Literature DB >> 21127198

ROS and CHOP are critical for dibenzylideneacetone to sensitize tumor cells to TRAIL through induction of death receptors and downregulation of cell survival proteins.

Sahdeo Prasad1, Vivek R Yadav, Jayaraj Ravindran, Bharat B Aggarwal.   

Abstract

Because tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) selectively kills tumor cells, it is being tested in cancer patients. Unfortunately, patients develop resistance to the cytokine, therefore, agents that can sensitize cells to TRAIL are urgently needed. In this study, we investigated whether dibenzylideneacetone (DBA) can sensitize cancer cells to TRAIL and potentiates TRAIL-induced apoptosis. As indicated by accumulation of the membrane phospholipid phosphatidylserine, DNA breaks, intracellular esterase activity, and activation of caspase-8, -9, and -3, we concluded that DBA potentiated TRAIL-induced apoptosis in colon cancer cells. DBA also converted TRAIL resistant-cells to TRAIL-sensitive. When examined for the mechanism, we found that DBA decreased the expression of antiapoptotic proteins and decoy receptor-2 and increased proapoptotic proteins. DBA also induced both death receptor (DR)-5 and DR4. Knockdown of DR5 and DR4 by small interfering RNA (SiRNA) reduced the sensitizing effect of DBA on TRAIL-induced apoptosis. In addition, DBA increased the expression of CHOP proteins. Knockdown of CHOP by siRNA decreased the induction of DBA-induced DR5 expression and apoptosis. Induction of receptors by DBA, however, was p53-independent, as deletion of p53 had no effect on receptor induction. We observed that DBA-induced induction of DR5 and DR4 was mediated through generation of reactive oxygen species (ROS), as N-acetylcysteine blocked the induction of death receptors and suppression of cell survival proteins by DBA. Overall, our results show that DBA potentiates TRAIL-induced apoptosis through downregulation of cell survival proteins and upregulation of death receptors via activation of ROS and CHOP mediated pathways.
© 2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21127198      PMCID: PMC3022089          DOI: 10.1158/0008-5472.CAN-10-3121

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  48 in total

1.  The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis.

Authors:  R D Meng; E R McDonald; M S Sheikh; A J Fornace; W S El-Deiry
Journal:  Mol Ther       Date:  2000-02       Impact factor: 11.454

2.  Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site.

Authors:  R Takimoto; W S El-Deiry
Journal:  Oncogene       Date:  2000-03-30       Impact factor: 9.867

3.  Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo.

Authors:  T F Burns; E J Bernhard; W S El-Deiry
Journal:  Oncogene       Date:  2001-08-02       Impact factor: 9.867

4.  Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions.

Authors:  D Lawrence; Z Shahrokh; S Marsters; K Achilles; D Shih; B Mounho; K Hillan; K Totpal; L DeForge; P Schow; J Hooley; S Sherwood; R Pai; S Leung; L Khan; B Gliniak; J Bussiere; C A Smith; S S Strom; S Kelley; J A Fox; D Thomas; A Ashkenazi
Journal:  Nat Med       Date:  2001-04       Impact factor: 53.440

5.  Selective Akt inactivation and tumor necrosis actor-related apoptosis-inducing ligand sensitization of renal cancer cells by low concentrations of paclitaxel.

Authors:  Junichi Asakuma; Makoto Sumitomo; Takako Asano; Tomohiko Asano; Masamichi Hayakawa
Journal:  Cancer Res       Date:  2003-03-15       Impact factor: 12.701

6.  TRAIL-induced apoptosis and gene induction in HaCaT keratinocytes: differential contribution of TRAIL receptors 1 and 2.

Authors:  Martin Leverkus; Martin R Sprick; Tina Wachter; Andrea Denk; Eva-Bettina Bröcker; Henning Walczak; Manfred Neumann
Journal:  J Invest Dermatol       Date:  2003-07       Impact factor: 8.551

7.  CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells.

Authors:  Hirohito Yamaguchi; Hong-Gang Wang
Journal:  J Biol Chem       Date:  2004-08-18       Impact factor: 5.157

8.  Upregulation of FLIP(S) by Akt, a possible inhibition mechanism of TRAIL-induced apoptosis in human gastric cancers.

Authors:  Seon Young Nam; Gyung-Ah Jung; Gwong-Cheung Hur; Hee-Yong Chung; Woo Ho Kim; Dai-Wu Seol; Byung Lan Lee
Journal:  Cancer Sci       Date:  2003-12       Impact factor: 6.716

9.  Glycogen synthase kinase-3beta suppression eliminates tumor necrosis factor-related apoptosis-inducing ligand resistance in prostate cancer.

Authors:  Xinbo Liao; Liping Zhang; J Brantley Thrasher; Jie Du; Benyi Li
Journal:  Mol Cancer Ther       Date:  2003-11       Impact factor: 6.261

Review 10.  Apo2L/TRAIL and its death and decoy receptors.

Authors:  H N LeBlanc; A Ashkenazi
Journal:  Cell Death Differ       Date:  2003-01       Impact factor: 15.828

View more
  27 in total

1.  Retraction: ROS and CHOP Are Critical for Dibenzylideneacetone to Sensitize Tumor Cells to TRAIL through Induction of Death Receptors and Downregulation of Cell Survival Proteins.

Authors: 
Journal:  Cancer Res       Date:  2018-09-01       Impact factor: 12.701

2.  Cardamonin sensitizes tumour cells to TRAIL through ROS- and CHOP-mediated up-regulation of death receptors and down-regulation of survival proteins.

Authors:  Vivek R Yadav; Sahdeo Prasad; Bharat B Aggarwal
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

3.  Indomethacin sensitizes TRAIL-resistant melanoma cells to TRAIL-induced apoptosis through ROS-mediated upregulation of death receptor 5 and downregulation of survivin.

Authors:  Anfernee Kai-Wing Tse; Hui-Hui Cao; Chi-Yan Cheng; Hiu-Yee Kwan; Hua Yu; Wang-Fun Fong; Zhi-Ling Yu
Journal:  J Invest Dermatol       Date:  2013-11-08       Impact factor: 8.551

4.  Dibenzylideneacetones Are Potent Trypanocidal Compounds That Affect the Trypanosoma cruzi Redox System.

Authors:  Danielle Lazarin-Bidóia; Vânia Cristina Desoti; Solange Cardoso Martins; Fabianne Martins Ribeiro; Zia Ud Din; Edson Rodrigues-Filho; Tânia Ueda-Nakamura; Celso Vataru Nakamura; Sueli de Oliveira Silva
Journal:  Antimicrob Agents Chemother       Date:  2015-11-23       Impact factor: 5.191

5.  The orphan nuclear receptor NR4A1 (Nur77) regulates oxidative and endoplasmic reticulum stress in pancreatic cancer cells.

Authors:  Syng-Ook Lee; Un-Ho Jin; Jeong Han Kang; Sang Bae Kim; Aaron S Guthrie; Sandeep Sreevalsan; Ju-Seog Lee; Stephen Safe
Journal:  Mol Cancer Res       Date:  2014-02-10       Impact factor: 5.852

6.  Aldose reductase inhibition enhances TRAIL-induced human colon cancer cell apoptosis through AKT/FOXO3a-dependent upregulation of death receptors.

Authors:  Mohammad Shoeb; Kota V Ramana; Satish K Srivastava
Journal:  Free Radic Biol Med       Date:  2013-05-31       Impact factor: 7.376

7.  Identification of a novel compound (β-sesquiphellandrene) from turmeric (Curcuma longa) with anticancer potential: comparison with curcumin.

Authors:  Amit Kumar Tyagi; Sahdeo Prasad; Wei Yuan; Shiyou Li; Bharat B Aggarwal
Journal:  Invest New Drugs       Date:  2015-11-02       Impact factor: 3.850

8.  Sensitivity of malignant peripheral nerve sheath tumor cells to TRAIL is augmented by loss of NF1 through modulation of MYC/MAD and is potentiated by curcumin through induction of ROS.

Authors:  David E Reuss; Jana Mucha; Christian Hagenlocher; Volker Ehemann; Lan Kluwe; Victor Mautner; Andreas von Deimling
Journal:  PLoS One       Date:  2013-02-21       Impact factor: 3.240

Review 9.  Molecular targets of TRAIL-sensitizing agents in colorectal cancer.

Authors:  Carmine Stolfi; Francesco Pallone; Giovanni Monteleone
Journal:  Int J Mol Sci       Date:  2012-06-25       Impact factor: 6.208

10.  Phosphorylated IκBα predicts poor prognosis in activated B-cell lymphoma and its inhibition with thymoquinone induces apoptosis via ROS release.

Authors:  Azhar R Hussain; Shahab Uddin; Maqbool Ahmed; Fouad Al-Dayel; Prashant P Bavi; Khawla S Al-Kuraya
Journal:  PLoS One       Date:  2013-03-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.